Any member of the class of piperidines in which one of the carbons of the piperidine ring is substituted by a carboxy group.
ChEBI ID: 26148
Member | Definition | Role |
---|---|---|
2,2,6,6-tetramethylpiperidine-n-oxide-4-amino-4-carboxylic acid | TOAC | |
5-hydroxypipecolic acid | A piperidinemonocarboxylic acid that is pipecolic acid with a hydroxy substituent at position 5. | 5-hydroxypipecolic acid |
delta(1)-piperidine-2-carboxylic acid | 1-piperideine-2-carboxylic acid zwitterion; 1-piperideine-2-carboxylic acid | |
difenoxin | A piperidinemonocarboxylic acid that is 4-phenylpiperidine-4-carboxylic acid in which the hydrogen attached to the nitrogen atom is substituted by a 3-cyano-3,3-diphenylpropyl group. | difenoxin |
N-hydroxypipecolic acid | An N-hydroxy-alpha-amino-acid resulting from the formal N-hydroxylation of the amino group of piperidine-carboxylic acid (pipecolic acid). | N-hydroxypipecolic acid |
nipecotic acid | A piperidinemonocarboxylic acid that is piperidine in which one of the hydrogens at position 3 is substituted by a carboxylic acid group. | nipecotic acid |
pipecolic acid | A piperidinemonocarboxylic acid in which the carboxy group is located at position C-2. | pipecolic acid |
tempo carboxylic acid | A member of the class of aminoxyls that is TEMPO carrying a carboxy group at position 4. | 4-carboxy-TEMPO |
tiagabine | A piperidinemonocarboxylic acid that is (R)-nipecotic acid in which the hydrogen attached to the nitrogen has been replaced by a 1,1-bis(3-methyl-2-thienyl)but-1-en-4-yl group. A GABA reuptake inhibitor, it is used (generally as the hydrochloride salt) for the treatment of epilepsy. | tiagabine |
Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
---|---|---|
pre-1990 | 167 (13.59) | 18.7374 |
1990's | 308 (25.06) | 18.2507 |
2000's | 422 (34.34) | 29.6817 |
2010's | 258 (20.99) | 24.3611 |
2020's | 74 (6.02) | 2.80 |
Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
---|---|---|
Trials | 106 (7.17%) | 5.53% |
Reviews | 131 (8.86%) | 6.00% |
Case Studies | 88 (5.95%) | 4.05% |
Observational | 1 (0.07%) | 0.25% |
Other | 1,153 (77.96%) | 84.16% |